Immatics nabs former GSK exec as CMO; announces other moves

4 June 2020
immatics-logo-big

Privately-held German firm Immatics Biotechnologies today announced that Cedrik Britten has been appointed as chief medical officer (CMO) effective June 1, 2020.

Trained as a physician, Dr Britten will join Immatics with more than a decade of experience in clinical development including his most recent position as vice president and head of the Oncology Cell Therapy Research Unit at GlaxoSmithKline (LSE: GSK. He will be responsible for the management and global development of Immatics’ clinical pipeline. Prior to GSK, he held various senior positions at BioNTech including vice president for R&D.

Current CMO becomes chief development officer

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology